On August 18, 2026, the U.S. Food and Drug Administration (FDA) offered new insight into how it may approach the regulation of generative AI-enabled medical devices: a two-axis risk framework and a competency-based evaluation model spanning benchmarking, clinical confirmation, and post market monitoring. As we detailed in our recent client alert, the agency is seeking comments through October 19, 2026, a narrow window to shape policy while the framework is still taking form.
Join Wilson Sonsini partners Jodi Daniel and Eva Yin, and Of Counsel Ty Kayam, who previously served as the first attorney in the FDA's Digital Health Center of Excellence, for a focused session on what the discussion paper means for developers, sponsors, and platform providers; the open questions the FDA is asking stakeholders to answer; and how to submit an effective comment before the deadline.
